The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Talipexol     4-prop-2-enyl-10-thia-4,8...

Synonyms: Talipexole, Talipexolum, CHEMBL279085, B-HT 920, AG-J-06186, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of talipexole hydrochloride


Psychiatry related information on talipexole hydrochloride


High impact information on talipexole hydrochloride

  • In contrast, pretreatment with 1 mM talipexole for 4 days markedly protected the cells against MPP+-induced apoptosis [7].
  • Simultaneous treatment with 1 mM talipexole slightly inhibited the MPP+-induced ROS production and apoptotic cell death [7].
  • These results suggest that talipexole has dual actions: (1) it directly scavenges ROS, affording slight protection against MPP+-induced apoptosis, and (2) it induces Bcl-2 expression, thereby affording more potent protection, if it is administrated before MPP+ [7].
  • In conclusion, in distinction to talipexole and quinelorane, and reflecting its antagonist properties at alpha(2A)-ARs, piribedil reinforces cholinergic transmission in the frontal cortex and dorsal hippocampus of freely moving rats [8].
  • Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors [8].

Chemical compound and disease context of talipexole hydrochloride


Biological context of talipexole hydrochloride


Anatomical context of talipexole hydrochloride

  • These findings suggest that talipexole acts as a D2 agonist on the striatal neurons receiving input from substantia nigra pars compacta and increases firing when intravenously applied.(ABSTRACT TRUNCATED AT 250 WORDS)[13]
  • The positive chronotropic responses to preganglionic stellate stimulation were inhibited by R(+)SK&F38393 and talipexole administered directly to the ganglia through the artery, and the inhibitory effects were antagonized by pretreatment with R(+)SCH23390 and S(-)sulpiride, respectively [14].
  • The acetylcholine output from the isolated stellate ganglia by preganglionic stimulation (5 Hz) was unaffected in the presence of (-)quinpirole and talipexole, but was concentration-dependently reduced in the presence of R(+)SK&F38393, and the reduction was antagonized by R(+)SCH23390 [14].
  • TA-993 (300 microg/kg i.v.) did not alter the phenylephrine (1-100 ng/kg i.a.)- or the talipexole (3-100 ng/kg i.a.)-induced increase in perfusion pressure in an autoperfused hindlimb [15].
  • Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole [16].

Associations of talipexole hydrochloride with other chemical compounds


Gene context of talipexole hydrochloride


Analytical, diagnostic and therapeutic context of talipexole hydrochloride


  1. Effects on body temperature in mice differentiate between dopamine D2 receptor agonists with high and low efficacies. Sánchez, C., Arnt, J. Eur. J. Pharmacol. (1992) [Pubmed]
  2. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment. Irifune, M., Nomoto, M., Fukuda, T. Eur. J. Pharmacol. (1994) [Pubmed]
  3. Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets. Irifune, M., Nomoto, M., Fukuda, T. Eur. J. Pharmacol. (1993) [Pubmed]
  4. Hyperthermia induced by the dopamine D1 receptor agonist SK&F38393 in combination with the dopamine D2 receptor agonist talipexole in the rat. Nagashima, M., Yamada, K., Kimura, H., Matsumoto, S., Furukawa, T. Pharmacol. Biochem. Behav. (1992) [Pubmed]
  5. Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model. Kitamura, Y., Kakimura, J., Taniguchi, T. Jpn. J. Pharmacol. (1998) [Pubmed]
  6. Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial. Goetz, C.G., Stebbins, G.T., Thelen, J.A. Mov. Disord. (1994) [Pubmed]
  7. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Kitamura, Y., Kosaka, T., Kakimura, J.I., Matsuoka, Y., Kohno, Y., Nomura, Y., Taniguchi, T. Mol. Pharmacol. (1998) [Pubmed]
  8. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. Gobert, A., Di Cara, B., Cistarelli, L., Millan, M.J. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  9. Antagonism by pimozide of olanzapine-induced hypothermia. Ninan, I., Kulkarni, S.K. Fundamental & clinical pharmacology. (1999) [Pubmed]
  10. Chronic treatment with talipexole dihydrochloride on abnormal involuntary movement in humans. Nishikawa, T., Yamada, S., Tsuda, A., Tanaka, M., Koga, I., Uchida, Y. Clinical neuropharmacology. (1990) [Pubmed]
  11. Effects of anti-Parkinsonian drugs on neurobehavioural changes induced by bilateral 6-hydroxydopamine lesions in rats. Hayakawa, T., Sugimoto, Y., Chen, Z., Fujii, Y., Kamei, C. Clin. Exp. Pharmacol. Physiol. (1999) [Pubmed]
  12. Hypotensive and bradycardic effects of talipexole (B-HT 920) in anaesthetized rabbits are antagonized by metoclopramide but not by yohimbine. Palluk, R., Schilling, J.C., Stockhaus, K., Peil, H. Naunyn Schmiedebergs Arch. Pharmacol. (1993) [Pubmed]
  13. Action of intravenously administered talipexole on the rat striatal neurons receiving excitatory input from nigral dopamine neurons. Matsubayashi, H., Amano, T., Hongjing, Y., Kohno, Y., Sasa, M. Psychopharmacology (Berl.) (1995) [Pubmed]
  14. The inhibition of ganglionic transmission via presynaptic dopamine DA1 and postsynaptic DA2 receptor activation in the canine cardiac sympathetic ganglia. Mukai, M., Kushiku, K., Yamada, H., Yamada, K., Dan, K., Furukawa, T. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  15. The mechanism of the increasing action of TA-993, a new 1,5- benzothiazepine derivative, on limb blood flow in anesthetized dogs: selective suppression of sympathetic nerve activity. Kaburaki, M., Yabana, H., Doi, H., Nagata, K., Narita, H., Murata, S. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
  16. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Takata, K., Kitamura, Y., Kakimura, J., Kohno, Y., Taniguchi, T. Brain Res. (2000) [Pubmed]
  17. Possible involvement of differing classes of dopamine D-2 receptors in yawning and stereotypy in rats. Yamada, K., Nagashima, M., Kimura, H., Matsumoto, S., Furukawa, T. Psychopharmacology (Berl.) (1990) [Pubmed]
  18. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. Inoue, T., Domae, M., Yamada, K., Furukawa, T. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  19. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects. Meltzer, L.T., Christoffersen, C.L., Corbin, A.E., Ninteman, F.W., Serpa, K.A., Wiley, J.N., Wise, L.D., Heffner, T.G. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  20. Modulation of N-methyl-D-aspartate (NMDA)-stimulated noradrenaline release in rat brain cortex by presynaptic alpha 2-adrenoceptors. Fink, K., Göthert, M. Naunyn Schmiedebergs Arch. Pharmacol. (1993) [Pubmed]
  21. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Kakimura, J., Kitamura, Y., Takata, K., Kohno, Y., Nomura, Y., Taniguchi, T. Eur. J. Pharmacol. (2001) [Pubmed]
  22. Further characterization of the ORL1 receptor-mediated inhibition of noradrenaline release in the mouse brain in vitro. Werthwein, S., Bauer, U., Nakazi, M., Kathmann, M., Schlicker, E. Br. J. Pharmacol. (1999) [Pubmed]
  23. Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum. Kohno, Y., Fukuzaki, K., Kitahara, K., Koja, T. Eur. J. Pharmacol. (1997) [Pubmed]
  24. Talipexole protects dopaminergic neurons from methamphetamine toxicity in C57BL/6N mouse. Kondo, T., Shimada, H., Hatori, K., Sugita, Y., Mizuno, Y. Neurosci. Lett. (1998) [Pubmed]
  25. D2 receptor activation in distinct striatal neurons in comparison with D3 receptors. Sasa, M., Ishihara, K., Amano, T., Matsubayashi, H., Momiyama, T., Todo, N. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. (1997) [Pubmed]
WikiGenes - Universities